Fos-related antigen-1 (Fra-1) is a member of the Activator Protein-1 (AP-1) transcription factor superfamily that is overexpressed in a variety of cancers, including colon, breast, lung, bladder and brain. High Fra-1 levels are associated with enhanced cell proliferation, survival, migration and invasion. Despite its frequent overexpression, the molecular mechanisms that regulate the accumulation of Fra-1 proteins in tumour cells are not well understood. Here, we show that turnover of Fra-1, which does not require ubiquitylation, is cooperatively regulated by two distinct mechanisms-association with the 19S proteasomal subunit, TBP-1, and by a C-terminal degron, which acts independently of TBP-1, but is regulated by RAS-ERK (extracellular signal-regulated kinase) signalling. TBP-1 depletion stabilized Fra-1 and further increased its levels in tumour cells expressing RAS-ERK pathway oncogenes. These effects correlated with increased AP-1 transcriptional activity. We suggest that during Fra-1 degradation, association with TBP-1 provides a mechanism for ubiquitin-independent proteasomal recognition, while the C terminus of the protein regulates its subsequent proteolytic processing.
Introduction
Activator Protein-1 (AP-1) transcription factors are dynamic regulators of gene expression that consist members of the Fos, Jun, ATF and MAF families. These proteins form dimers that recognize the TPAresponse element and other consensus motifs (for example, CRE, ARE, NFkB, E2F) in the promoter/ enhancer regions of genes that regulate cell proliferation, survival, differentiation and migration (Karin et al., 1997; Chinenov and Kerppola, 2001) .
Dysregulated expression of specific AP-1 proteins is strongly linked with malignancy. The Fos-related antigen-1 (Fra-1) is a Fos family member that is persistently overexpressed in a variety of cancers and tumour cell lines, where it has been reported to regulate cell proliferation, survival, migration and invasion Belguise et al., 2005; Debinski and Gibo, 2005; Pollock et al., 2005; Kakumoto et al., 2006; Young and Colburn, 2006; Adiseshaiah et al., 2007; Casalino et al., 2007; Doehn et al., 2009; Luo et al., 2010) . A number of Fra-1-regulated genes have been implicated in these processes, including modulators of cell cycle progression (CCND1 and CCNA2; Burch et al., 2004; Casalino et al., 2007; Vikhanskaya et al., 2007) , epithelial-mesenchymal transitions (ZEB1 and ZEB2; Shin et al., 2010, extracellular matrix degradation (MMP1 and MMP9; Kustikova et al., 1998) and migration (cd44, VEGF, c-met; Ramos-Nino et al., 2003) .
A critical but unresolved issue is how Fra-1 accumulates to high levels in tumour cells. Fra-1 is an intrinsically unstable, short-lived protein, whose synthesis and stability is predominantly regulated by the RAS-ERK (extracellular signal-regulated kinase) pathway Basbous et al., 2007) . Activation of the pathway induces transcription of the Fra-1 gene (fosl1), and phosphorylation of the protein on Ser 252 and Ser
265
, which are located in a C-terminal degron known as the destabilizer (DEST) domain. Phosphorylation of this region of Fra-1 increases its stability, and is likely to be important for its accumulation in tumour cells where the RAS-ERK pathway is persistently activated by KRAS or BRAF oncogenes (Basbous et al., 2007) . In addition, in cells expressing RAS oncogenes, heterodimerization with Fra-1 has been reported to prevent degradation of cJun, and thus favours the formation of AP-1 complexes consisting of Fra-1/c-Jun (Talotta et al., 2003) .
The best understood mechanism of directing proteins to the proteasome for destruction is via the covalent attachment of ubiquitin chains to lysine residues within, or in their N-termini. However, a growing number of proteasomal substrates do not appear to require prior ubiquitylation to be degraded (Hoyt and Coffino, 2004; Jariel-Encontre et al., 2008; Baugh et al., 2009) . Fra-1 is one such protein, undergoing properly regulated proteasomal degradation even when all its lysine residues are substituted with arginines and its N terminus is blocked by fusion to a myc-epitope tag (Basbous et al., 2007 . Other examples of cancer-associated proteins that can undergo ubiquitin-independent proteasomal degradation include c-Fos , p21 (Chen et al., 2007b) , Rb (Kalejta and Shenk, 2003) , KLF5 (Chen et al., 2007a) , p53 and p73 (Asher et al., 2005) . Although not well understood at the molecular level, ubiquitin-independent proteolysis may involve specific protein-protein interactions and the presence of poorly structured protein domains that can be recognized by proteasomal components (JarielEncontre et al., 2008) .
In this study, we investigated how ubiquitin-independent turnover of Fra-1 proteins is regulated. We report that this process requires association of Fra-1 with the TBP-1 subunit of the 19S proteasome. Depletion of TBP-1, increased Fra-1 levels and stability in tumour cell lines in which the RAS-ERK persistently activated and increased AP-1-dependent transcription. We found that deletion of the three C-terminal residues of Fra-1 or phosphomimetic substitutions of ERK-regulated sites also stabilized the protein, but via a mechanism distinct to TBP-1 binding. Our findings suggest a model in which TBP-1-mediated association of non-ubiquitylated Fra-1 with the proteasome cooperates with a C-terminal, ERK-regulated degron to control turnover and accumulation of Fra-1 in tumour cells.
Results
Fra-1 associates with TBP-1 subunit of the 19S proteasome To investigate the possibility that ubiquitin-independent turnover of Fra-1 involves direct association with proteasomal components, we used mass spectrometry to search for proteasomal subunits that can interact with Fra-1. As wild-type Fra-1 (Fra-1 WT ) is unstable, we employed two approaches to generate sufficient bait protein for mass spectrometry. First, we deleted the three C-terminal residues of Fra-1, which are conserved among Fos family members, and have been shown to destabilize c-Fos (Acquaviva et al., 2001) . Deletion of these residues robustly enhanced Fra-1 expression by an extent comparable to deletion of the entire DEST domain (Fra-1
D50
; Figures 1a and b) , suggesting that these residues have a critical role in destabilizing the protein.
Despite their enhanced stability, Fra-1 D3 proteins retained the ability to undergo proteasome-dependent degradation ( Figure 1c) . We also analyzed the composition of Fra-1 WT complexes by purifying the protein from cells coexpressing the BRAF kinase, which induced phosphorylation and stabilization of Fra-1 (Figure 1d ).
The major proteasomal component that we identified in FLAG-Fra-1 D3 and FLAG-Fra-1 WT /BRAF complexes was TBP-1 (Figure 1e ; also known as PRS6A/Rpt5/S6'), one of six AAA ATPases that forms the lid of the 19S proteasome regulatory particle (Finley, 2009; Gallastegui and Groll, 2010) . No peptides corresponding to TBP-1 were detected in anti-FLAG immunoprecipitates from cells transfected with vector alone.
We used coimmunoprecipitation analysis to confirm that TBP-1 associates with Fra-1 D3 and Fra-1 WT in HEK293 cells (Figure 2a) . Treatment of the cells with the mitogen TPA to induce phosphorylation and Regulation of Fra-1 turnover JL Pakay et al activation of Fra-1 (Young et al., 2002) did not alter the abundance of Fra-1/TBP-1 complexes. However, TBP-1 immunoprecipitates contained Fra-1 species of differing mobilities on SDS-polyacrylamide gel electrophoresis gels, a likely indication that multiple phosphorylation states of the protein were present .
In KRAS mutant HCT116 colon carcinoma cells, which express high levels of endogenous Fra-1 (Pollock et al., 2005) , we found that endogenous TBP-1 was present in immunoprecipitates prepared using anti-Fra-1 but not control (IgG) antibodies (Figure 2b ), and that only a small proportion of the TBP-1 in these cells was associated with Fra-1. In contrast to Fra-1, we found that c-Fos did not associate with TBP-1 in HEK293 cells (Figure 2c ), indicating the capacity to interact with TBP-1 was not a property shared by all Fos family members.
To identify the Fra-1 residues that are required for association with TBP-1, we used coimmunoprecipitation assays to test TBP-1 binding to a series of Fra-1 deletion mutants (Fra-1
) in HEK293 cells ( Figure 2d ). These experiments revealed that TBP-1 interacts with a stretch of 51 residues (169-220) that lie between the bZIP and DEST domains of Fra-1.
Next, to examine whether Fra-1 and TBP-1 can interact with TBP-1 in vitro, immunopurified FLAG-TBP-1 was incubated with immunoprecipitates containing GFP (green fluorescent protein), GFP-Tam67 (an inactive c-Jun mutant that retains the capacity to bind Fra-1; Dong et al., 1996) and GFP-Fra-1 (Figure 2e ). Only GFP-Fra-1 bound to FLAG-TBP-1 in this assay, demonstrating the specificity and potentially direct nature of the interaction. This was further confirmed by testing in vitro translated proteins, which showed that Fra-1 but not c-Fos bound directly to TBP-1 (Figure 2f ). Together, these findings provide strong evidence that TBP-1 is a bona fide Fra-1-interacting protein in human cells.
TBP-1 regulates Fra-1 levels in tumour cells As TBP-1 has been reported to interact with both ubiquitylated and non-ubiquitylated proteasomal substrates (Lam et al., 2002; Zhang et al., 2003) , we hypothesized that TBP-1 binding could provide a mechanism for proteasomal recognition of non-ubiquitylated Fra-1, and therefore has a key role in its degradation. We tested this possibility by silencing TBP-1 expression in three cancer cell lines expressing oncogenic ERK pathway components, MDA-MB-231 (KRAS mutant), BE (KRAS and BRAF mutant) and HCT116 (KRAS mutant). We found that a 51-73% reduction in TBP-1 levels resulted in a 1.6-4.1-fold increase Fra-1 abundance in all three tumour cell lines (Figures 3a-c) . Conversely, overexpression of TBP-1 reduced endogenous Fra-1 protein levels in HCT116 cells (Figure 3d ), which was prevented upon proteasomal inhibition using MG132. These data demonstrate that endogenous TBP-1 is a negative regulator of Fra-1 levels in cancer cells expressing oncogenic components of the RAS-ERK pathway.
TBP-1 modulates Fra-1 turnover To determine whether TBP-1 functions as a regulator of Fra-1 stability, we monitored the rate of Fra-1 disappearance upon inhibition of protein synthesis with cycloheximide. In HCT116 cells treated with control small interfering RNA (siRNA), Fra-1 had a half-life of B40 min, whereas in TBP-1-depleted cells, 60-70% of Fra-1 remained after 2 h of cycloheximide treatment (Figures 4a and b) . Interestingly, we noted that differentially phosphorylated Fra-1 proteins degraded with varying kinetics (Figure 4a) , with the fastest migrating species being most strongly stabilized by TBP-1 knockdown. Slower migrating forms of Fra-1 were phosphorylated on the ERK MAPK-regulated site, Ser 265 ( Figure 4c ). These findings suggest that endogenous TBP-1 regulates Fra-1 levels in tumour cells by regulating protein turnover.
TBP-1 and ERK signalling regulate Fra-1 turnover by distinct mechanisms Like the effects of TBP-1 silencing, deletion or phosphomimetic substitution of ERK-regulated sites in the DEST domain of Fra-1 enhances protein stability (Basbous et al., 2007) , suggesting that these two phenomenon are mechanistically linked. One obvious possibility was that ERK-induced phosphorylation of the DEST domain disrupts binding of Fra-1 to TBP-1, and thereby stabilizes Fra-1. We found this not to be the case, as Fra-1 variants lacking the entire DEST domain (Fra-1
) retained the ability to associate with TBP-1 (Figure 5a ). We also noted that Fra-1 proteins containing aspartic acid (Fra-1 DD ) or alanine (Fra-1 AA ) substitutions of Ser 252 and Ser 265 associated with similar amounts of TBP-1 (Figure 5b ). These results indicate that the ability of the DEST domain to confer instability to Fra-1 does not involve TBP-1 binding.
To further explore the relationship between TBP-1 binding and ERK-mediated stabilization of Fra-1, we tested whether, like Fra-1 WT , Fra-1 DD levels increased upon TBP-1 depletion. Figure 5c shows that silencing TBP-1 expression not only resulted in a robust increase in Fra-1 WT levels, but also further enhanced Fra-1 DD expression, albeit to a lesser extent. In contrast, we found that endogenous c-Jun levels were not affected by TBP-1 depletion. Thus, the mechanisms by which TBP-1 silencing and ERK-regulated phosphorylation stabilize Fra-1 appear to be distinct.
Next, we examined the role of the bZIP domain of Fra-1 in TBP-1-mediated regulation of Fra-1 turnover. We found that the stabilizing effect of TBP-1 depletion did not require binding of Fra-1 to DNA or its dimerization with other AP-1 proteins, because TBP-1 Regulation of Fra-1 turnover JL Pakay et al silencing increased the levels of Fra-1 variants that were defective in both these functions to a similar extent as Fra-1 WT (Figure 5d ).
TBP-1 regulates AP-1-dependent transcription
To determine whether endogenous TBP-1 modulates Fra-1-induced gene expression, we examined the activity of an AP-1 reporter gene. We found that TBP-1 overexpression reduced basal and Fra-1-induced activation of the AP-1 reporter gene by B30% (Figure 6a ). In contrast, TBP-1 depletion increased basal, Fra-1
WT
and Fra-1 DD -induced AP-1 transcriptional activation (Figure 6b) . Interestingly, the fold increase AP-1 activity upon TBP-1 depletion was similar in cells expressing Fra-1 WT and Fra-1 DD , despite the more dramatic effect on Fra-1 WT protein levels (see Figure 5c ). We noted a significant increase in basal AP-1 reporter gene activity upon TBP-1 depletion (Figure 6b ). This increase was dependent on Fra-1 because it was suppressed when the cells were treated with a combination of TBP-1 and Fra-1 siRNAs or by expression of a DNA binding-defective Fra-1 variant (Figure 6b ). Together, these findings demonstrate that TBP-1 is required for the turnover of transcriptionally competent Fra-1 proteins and is therefore likely to have an important role in regulating Fra-1-mediated gene expression.
Discussion
Overexpression of the Fra-1 transcription factor in human cancers is strongly linked to tumour growth, migration and invasion Belguise et al., 2005; Debinski and Gibo, 2005; Pollock et al., 2005; Young and Colburn, 2006; Adiseshaiah et al., 2007; Doehn et al., 2009; Luo et al., 2010) . Understanding the mechanisms regulating Fra-1 accumulation in tumour cells is a key issue, but one that is not fully understood. In this study, we investigated how turnover of Fra-1 is regulated. We provide evidence of two critical requirements for this process, association with the 19S proteasomal subunit, TBP-1, and the presence of a short stretch of residues in the C terminus of the protein.
TBP-1 has been proposed to constitute part of a common proteasomal binding site for both ubiquitylated and non-ubiquitylated substrates (Zhang et al., 2003) . As turnover of Fra-1 does not require ubiquitylation (Basbous et al., 2007) , association with TBP-1 may fulfil a key requirement for degradation of the protein, which is to provide a means for ubiquitin-independent recognition and targeting to the proteasome.
In addition to requiring a mechanism for binding to the proteasome, the efficient degradation of proteasomal substrates can involve poorly structured regions in their termini, from which unfolding or degradation is initiated (Prakash et al., 2004; Takeuchi et al., 2007) . During ubiquitin-independent degradation of the enzyme ornithine decarboxylase, both these requirements are supplied by a stretch of 37 C-terminal residues (Takeuchi et al., 2007) . Like ornithine decarboxylase, Fra-1 contains a 30-40 residue long C-terminal region (DEST domain) that is poorly structured . We found that deletion of just three residues in this domain was sufficient to robustly enhance expression of the protein to an extent comparable to deletion of the entire DEST domain. These residues have also been reported to have a critical role in destabilizing the c-Fos protein (Acquaviva et al., 2001) . Surprisingly, Fra-1 proteins lacking these residues or the entire DEST domain retained the ability of Fra-1 to associate with TBP-1, indicating that TBP-1 binding alone is not sufficient for Fra-1 degradation. Based on these findings, we suggest a model in which TBP-1 regulates association of Fra-1 with the proteasome, while residues in the C terminus of the protein modulate a subsequent step in its proteolytic processing, such as insertion into the core of the 20S proteasome (Figure 7) .
A further prediction of our model is that ERK-induced phosphorylation of the Fra-1 C terminus leads to stabilization of the protein by inducing structural changes that interfere with proteolysis. Consistent with this postulate, we found that TBP-1 depletion enhanced the expression of Fra-1 variants containing phosphomimetic substitutions at Ser 252 and Ser
265
. In addition, TBP-1 depletion further elevated Fra-1 levels in tumour cell lines expressing KRAS and BRAF oncogenes, which persistently activate ERK signalling. Thus, the extent of accumulation in tumour cells is likely to be determined by a combination of ERK pathway activation and the level of TBP-1 expression. Previous studies have shown that in addition to being proteasome-bound, TBP-1 can associate with transcriptional complexes on chromatin (Satoh et al., 2009) . The presence of TBP-1 in Fra-1 complexes may thus facilitate their rapid turnover, providing a dynamic mechanism to regulate AP-1 activity. However, our chromatin immunoprecipitation analysis of the Fra-1 target gene VIM (Andreolas et al., 2008) found that only Fra-1 but not TBP-1 was present at the AP-1 site in the VIM gene promoter (Supplementary Figure 1) . These findings indicate that TBP-1 is not a component chromatin-bound Fra-1 complexes.
Although it is presently not known whether decreased TBP-1 expression correlates with elevated Fra-1 levels in cancer, a previous study has shown that TBP-1 expression is repressed by oncogenic erbB receptor kinases (Park et al., 1999) . This study also showed that TBP-1 has tumour-suppressive properties, a finding confirmed subsequently by other groups (Pollice et al., 2007) . Several proteins, whose cellular levels are regulated by TBP-1, may be involved in mediating its tumour-suppressive effects, including p14ARF (Pollice et al., 2007) , HIF1a (Corn et al., 2003) and Rb (Higashitsuji et al., 2000) . Our findings suggest that negative regulation of Fra-1 levels may also contribute to the ability of TBP-1 to act as a tumour suppressor.
Materials and methods
Cell culture and reagents HEK293, MDA-MB-231, HCT116, J82 and BE cells were grown in Dulbecco's modified Eagle's medium supplemented with 2 mM L-glutamine and 10% foetal calf serum. Cells were transfected with expression constructs using Lipofectamine 2000 or Lipfectamine LTX (Invitrogen, Melbourne, VIC, Australia). Cycloheximide and MG132 were from Merck (Melbourne, VIC, Australia), while TPA was purchased from Sigma (Sydney, NSW, Australia).
The expression constructs pCDNA3-FLAG-Fra-1 WT (Terasawa et al., 2003) and FLAG-TBP-1 (Ishizuka et al., 2001 ) have been described previously. The pCDNA3-HA-Fra-1 and pIRES-puro- Model of ubiquitin-independent Fra-1 turnover. In this model, ubiquitin-independent association of Fra-1 with the proteasome is mediated via interactions with the TBP-1 subunit of the 19S proteasome. This interaction does not involve the C-terminal DEST domain of Fra-1, which regulates processing of Fra-1 by the proteasome. The latter process is antagonized upon ERK-induced phosphorylation of Ser 252 and Ser 265 in the DEST domain, thereby stabilizing the protein.
Regulation of Fra-1 turnoverHA-Fra-1 D3 constructs were generated using standard PCR-based methods. Mutations to generate dimerization-defective (L154A/ L161A) and DNA binding-defective (R112V, R124V) variants of Fra-1 were introduced by site-directed mutagenesis. All constructs were verified by sequencing.
The siRNA oligonucleotides used in this study were from Dharmacon (Melbourne, VIC, Australia) (TBP-1 #1 , 5
0 -G GACAAUGCUGGAGCUUCU-3 0 ; TBP-1
#2
, 5 0 -CAAAGACU CCUAUCUGAUC-3 0 ) or Qiagen (Melbourne, VIC, Australia) (AllStars negative control siRNA), and were introduced into cells using DharmaFECT 1 reagent (Dharmacon).
Mass spectrometry
Eight 10-cm diameter dishes of HEK293 cells were transfected with pCDNA3, pCDNA3-FLAG-Fra-1 D3 or pCDNA3-FLAG-Fra-1
WT and wild-type BRAF. The cells were lysed after 48 h by passaging through a 23-G needle in Buffer A (20 mM Hepes (pH 8.0), 150 mM NaCl, 2 mM EDTA, 0.5% NP-40, 1 mM phenylmethylsulphonyl fluoride, 2 mM NaF, 1 mM Na vanadate, 5 mg/ml leupeptin and 2.2 mg/ml aprotinin). The cell extracts were incubated on ice for 20 min, cleared by centrifugation, and incubated with 80 ml of a-FLAG M2 affinity gel (Sigma) for 2 h. Immunoprecipitates were washed four times with Buffer A before elution of the FLAG-Fra-1
D3
complexes with FLAG peptide (0.1 mg/ml). Eluted proteins were separated on 4-12% NuPAGE gels (Invitrogen) and stained with Colloidal Coomassie (BioRad, Gladesville, NSW, Australia). Gel lanes of interest were sliced into multiple pieces and processed for analysis by mass spectrometry as described previously (von Kriegsheim et al., 2006) .
Immunoprecipitation and immunoblotting
Cells were lysed for immunoprecipitation analysis by passaging through a 23G needle in Buffer A. HEK293 cell extracts from each 10-cm diameter dish were incubated with 2 mg of a-GFP (Invitrogen) or a-HA (Roche, Sydney, NSW, Australia) antibodies and 20 ml of protein A-agarose beads (Sigma). AntiFra-1 immunoprecipitates were prepared from two 10-cm diameter dishes of HCT116 cells using 6 mg of a-Fra-1 antibody (R-20; Santa Cruz Biotechnologies, Scoresby, VIC, Australia) and 20 ml of protein A-agarose beads.
For in vitro binding assays, proteins were synthesized with the TNT-coupled in vitro transcription/translation kit (Promega, Sydney, NSW, Australia) using templates containing a T7 promoter. The two proteins were incubated overnight in Buffer A, following which anti-FLAG agarose beads were added to each sample for 2 h. The beads were washed three times in Buffer A before carrying out the analysis by immunoblotting.
SDS-polyacrylamide gel electrophoresis and transfer of proteins onto PVDF membranes (GE Healthcare, Rydalmere, NSW, Australia) was performed using standard protocols. The membranes were incubated with the following antibodies: a-FLAG M2 (Sigma); a-Fra-1, a-14-3-3 and a-tubulin (Santa Cruz Biotechnologies), a-HA (Roche), a-TBP-1 (Upstate Inc., Kilsyth, VIC, Australia), anti-GFP (Invitrogen) and anti-phospho ERK1/2 (Cell Signaling, Arundel, QLD, Australia). Protein bands were visualized using HRP-labelled secondary antibodies and detected with ECL reagents (Pierce, Scoresby, VIC, Australia).
Reporter gene assays HEK293 were transfected with control, TBP-1 or Fra-1 siRNA oligonucleotides (25 nM per well) in 24-well dishes. After 24 h, the cells were retransfected in quadruplicate with a total of 0.25 mg of pCDNA3, Fra-1 and/or TBP-1 expression constructs together with 0.5 mg pfLuc 5 Â AP-1 and 0.00625 mg pSV40-RL (as internal control) per well. At 48 h after retransfection, luciferase activity was measured using the Dual-Luciferase Reporter Assay (Promega). The normalized activities were expressed as fold of pcDNA3-transfected cells ± s.e.m. pfLUC 5 Â AP-1 is based on the pfLUC reporter construct with the minimal c-Fos promoter (Saksela and Baltimore, 1993) , but contains five copies of the TPA response element from the intronic enhancer of the S100A4 gene cloned in the HindIII site in a head-to-tail orientation (Cohn et al., 2001 ).
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